SE8704436D0 - USE OF ANTI-SECRETARY SUBSTANCES FOR NEW INDICATIONS - Google Patents

USE OF ANTI-SECRETARY SUBSTANCES FOR NEW INDICATIONS

Info

Publication number
SE8704436D0
SE8704436D0 SE8704436A SE8704436A SE8704436D0 SE 8704436 D0 SE8704436 D0 SE 8704436D0 SE 8704436 A SE8704436 A SE 8704436A SE 8704436 A SE8704436 A SE 8704436A SE 8704436 D0 SE8704436 D0 SE 8704436D0
Authority
SE
Sweden
Prior art keywords
receptor
diseases
blocking
secretary
substances
Prior art date
Application number
SE8704436A
Other languages
Swedish (sv)
Inventor
R Hakansson
Original Assignee
Pm Konsult Handelsbolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pm Konsult Handelsbolag filed Critical Pm Konsult Handelsbolag
Priority to SE8704436A priority Critical patent/SE8704436D0/en
Publication of SE8704436D0 publication Critical patent/SE8704436D0/en
Priority to EP88909854A priority patent/EP0338066A1/en
Priority to EP88910155A priority patent/EP0353262A1/en
Priority to HU886797A priority patent/HUT51894A/en
Priority to JP63509275A priority patent/JPH02502188A/en
Priority to AU26218/88A priority patent/AU2621888A/en
Priority to PCT/SE1988/000575 priority patent/WO1989003830A1/en
Priority to AU27203/88A priority patent/AU2720388A/en
Priority to HU886738A priority patent/HU886738D0/en
Priority to MYPI88001227A priority patent/MY103790A/en
Priority to PCT/SE1988/000573 priority patent/WO1989003829A1/en
Priority to KR1019890701208A priority patent/KR890701580A/en
Priority to AU26216/88A priority patent/AU617721B2/en
Priority to JP63508989A priority patent/JPH02501930A/en
Priority to PCT/SE1988/000574 priority patent/WO1989004178A1/en
Priority to IL88207A priority patent/IL88207A/en
Priority to IL88206A priority patent/IL88206A0/en
Priority to DK322289A priority patent/DK322289A/en
Priority to DK329289A priority patent/DK329289D0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method for the treatment of osteoporosis, Paget's disease of bone, hyperparathyroidism, malignant neoplasms causing hypercalcinemia, parodontal diseases and prosthetic and implant-related bone loss, comprising administration to a patient suffering therefrom, an amount of H2-receptor-blocking compound or a pharmaceutically acceptable salt thereof. H2-receptor-blocking compounds for use in the manufacture of a medicament for such diseases are also disclosed as well as pharmaceutical preparations containing an H2-receptor-blocking compound for use in the treatment of said diseases. The preferred H2-receptor-blocking compounds are cimetidine and ranitidine.
SE8704436A 1987-10-30 1987-11-13 USE OF ANTI-SECRETARY SUBSTANCES FOR NEW INDICATIONS SE8704436D0 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
SE8704436A SE8704436D0 (en) 1987-11-13 1987-11-13 USE OF ANTI-SECRETARY SUBSTANCES FOR NEW INDICATIONS
PCT/SE1988/000574 WO1989004178A1 (en) 1987-11-13 1988-10-27 New therapeutical use of h2-receptor-blocking compounds
HU886738A HU886738D0 (en) 1987-10-30 1988-10-27 Process for the preparation of pharmaceutical compositions against osteoporosis containing 2-pyridinyl-methyl-(sulfinyl or thio)-benzimidazoles
PCT/SE1988/000573 WO1989003829A1 (en) 1987-10-30 1988-10-27 Omeprazole for treatment of diseases related to bone loss
HU886797A HUT51894A (en) 1987-11-13 1988-10-27 Process for production of medical compositions against caries of bones
JP63509275A JPH02502188A (en) 1987-11-13 1988-10-27 Novel therapeutic uses
AU26218/88A AU2621888A (en) 1987-10-30 1988-10-27 Omeprazole for treatment of diseases related to bone loss
PCT/SE1988/000575 WO1989003830A1 (en) 1987-10-30 1988-10-27 2-pyridinylmethyl (sulfinyl or thio)benzimidazoles for treatment of diseases related to bone loss
AU27203/88A AU2720388A (en) 1987-11-13 1988-10-27 New therapeutical use of h2-receptor-blocking compounds
EP88909854A EP0338066A1 (en) 1987-10-30 1988-10-27 2-pyridinylmethyl (sulfinyl or thio)benzimidazoles for treatment of diseases related to bone loss
MYPI88001227A MY103790A (en) 1987-10-30 1988-10-27 Novel compound for the treatment of several bone affecting diseases
EP88910155A EP0353262A1 (en) 1987-11-13 1988-10-27 New therapeutical use of h 2?-receptor-blocking compounds
KR1019890701208A KR890701580A (en) 1987-10-30 1988-10-27 2-pyridinylmethyl (sulfinyl or thio) benzimidazole for the treatment of diseases related to bone loss
AU26216/88A AU617721B2 (en) 1987-10-30 1988-10-27 2-pyridinylmethyl (sulfinyl or thio) benzimidazoles for treatment of diseases related to bone loss
JP63508989A JPH02501930A (en) 1987-10-30 1988-10-27 Novel uses for pharmaceutical compounds
IL88206A IL88206A0 (en) 1987-10-30 1988-10-28 Benzimidazoles and compositions containing same
IL88207A IL88207A (en) 1987-10-30 1988-10-28 Pharmaceutical compositions for the treatment of osteoporosis containing imidazole compounds
DK322289A DK322289A (en) 1987-10-30 1989-06-28 2-PYRIDINYLMETHYL (SULFINYL OR TIO) -BENZIMIDAZOLES FOR TREATING BONE RELATIONSHIPS
DK329289A DK329289D0 (en) 1987-11-13 1989-07-03 NEW THERAPEUTIC USE OF H2 RECEPTOR BREAKING COMPOUNDS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8704436A SE8704436D0 (en) 1987-11-13 1987-11-13 USE OF ANTI-SECRETARY SUBSTANCES FOR NEW INDICATIONS

Publications (1)

Publication Number Publication Date
SE8704436D0 true SE8704436D0 (en) 1987-11-13

Family

ID=20370204

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8704436A SE8704436D0 (en) 1987-10-30 1987-11-13 USE OF ANTI-SECRETARY SUBSTANCES FOR NEW INDICATIONS

Country Status (7)

Country Link
EP (1) EP0353262A1 (en)
JP (1) JPH02502188A (en)
AU (1) AU2720388A (en)
DK (1) DK329289D0 (en)
HU (1) HUT51894A (en)
SE (1) SE8704436D0 (en)
WO (1) WO1989004178A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8629781D0 (en) * 1986-12-12 1987-01-21 Glaxo Group Ltd Pharmaceutical compositions
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
EP1175903A3 (en) * 1997-07-22 2002-12-18 MERCK & CO. INC. Method for inhibiting bone resorption
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
US10398705B2 (en) 2012-03-15 2019-09-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
WO2015007760A1 (en) 2013-07-19 2015-01-22 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
CN110721164A (en) 2013-12-04 2020-01-24 勃林格殷格翰动物保健有限公司 Improved pharmaceutical composition of pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
US4220653A (en) * 1979-01-24 1980-09-02 Vivino A Earl Administration of cimetidine to reduce appetite and facilitate weight loss in persons suffering from excessive weight
US4256743A (en) * 1979-02-22 1981-03-17 President And Fellows Of Harvard College Inhibition of bone resorption with H1 -blocking antihistamines
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
CA1239349A (en) * 1983-10-10 1988-07-19 Eberhard F. Gottwald Pharmaceutical composition containing cimetidine

Also Published As

Publication number Publication date
DK329289A (en) 1989-07-03
WO1989004178A1 (en) 1989-05-18
HUT51894A (en) 1990-06-28
DK329289D0 (en) 1989-07-03
EP0353262A1 (en) 1990-02-07
AU2720388A (en) 1989-06-01
HU886797D0 (en) 1990-05-28
JPH02502188A (en) 1990-07-19

Similar Documents

Publication Publication Date Title
SE8704248D0 (en) MEDICAL USE
NO166448C (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE TIAZOLIDE INDIANS.
IT1241996B (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RESPIRATORY DISORDERS AND METHOD FOR ITS APPLICATION.
IL99699A0 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
ZA888734B (en) Stabilized medicinal substances,a process for the preparation thereof,and stable medicinal formulations
EP0221041A3 (en) Benzimidazole derivatives, process for their preparation and their pharmaceutical use
DE3876877T2 (en) USE OF INDOLON DERIVATIVES FOR THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF PARKINSONISM.
IT1241997B (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RESPIRATORY DISORDERS AND METHOD FOR ITS APPLICATION.
ES2052028T3 (en) A METHOD FOR PREPARING ANTI-ATEROSCLEROTIC DIARILIC COMPOUNDS.
SE8704436D0 (en) USE OF ANTI-SECRETARY SUBSTANCES FOR NEW INDICATIONS
HUP9701777A2 (en) Use of raloxifene for producing pharmaceutical compositions for preventing breast cancer
BG60101A3 (en) Method for preparing of 4-fluoro-2-[[(4-methoxy-2-pyridinyl)methyl]thionil]-1h-benzimidazo le
MY103790A (en) Novel compound for the treatment of several bone affecting diseases
IT8219482A0 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ORAL CAVITY DISEASES.
ATE13488T1 (en) GALLIUM CHLORIDE, A NEW ANTI-CANCER AGENT.
ATE130192T1 (en) USE OF 15-DEOXYSPERGUALIN AS A MEDICINAL PRODUCT.
AU579295B2 (en) New thiazole derivatives, a process for the preparation thereof and pharmaceutical compositions containing them
NZ220539A (en) 1,4-dihydropyridine derivatives and pharmaceutical compositions
IT1259140B (en) Pharmaceutical formulations for the oral administration of calcitonin